SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

SimpleScreen Lung

FRNM·Freenome, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Commercialized (LDT launch)
Time to market
Already commercially available as a laboratory-developed test (LDT) as of October 20, 2026. A future FDA premarket approval submission is planned but no timeline has been announced.
Why 4/10
SimpleScreen Lung was already launched commercially as an LDT on October 20, 2026. There is no upcoming PDUFA or pivotal-readout date scheduled in the next ~12 months; the Breakthrough Device Designation (already granted in August 2026) expedites future FDA review but no filing date has been set. With the launch binary already past, the score reflects a commercial-stage product without a hard near-term catalyst.
Actionable Insight NEUTRAL

SimpleScreen Lung was launched as an LDT on October 20, 2026, so the key binary event has passed. Watch for the company's progress toward FDA premarket submission (expedited by Breakthrough Device Designation), commercial adoption metrics, and payer coverage decisions, which will drive the stock over the coming quarters.

Price Chart

Loading chart...

Executive Summary

SimpleScreen Lung is Freenome's blood-based, AI-powered multiomic lung cancer screening test, launched commercially on October 20, 2026 as a laboratory-developed test (LDT). It targets adults ages 50-80 with a heavy smoking history (>=20 pack-years) who are not currently in guideline-recommended screening. In an independent validation cohort, the test demonstrated 85% sensitivity at 50% specificity with a 99.8% negative predictive value. The FDA granted Breakthrough Device Designation in August 2026, which could accelerate a future premarket approval pathway. The launch came shortly after Freenome went public via SPAC (July 2026) and received FDA approval for its colorectal cancer test, SimpleScreen CRC (partnered with Abbott), which drove $183.5M in Q3 2026 revenue. With no imminent FDA decision date for SimpleScreen Lung, the stock's near-term trajectory hinges on commercial adoption of the LDT and progress toward a formal FDA submission.

How It Works

SimpleScreen Lung is a blood test that uses artificial intelligence to analyze multiple biological signals (DNA, proteins, and other molecules) from a standard blood draw to detect early signs of lung cancer. It is designed for people aged 50 to 80 who have a significant smoking history (at least 20 pack-years) and are not already getting regular lung cancer screening. The test looks for patterns in the blood that suggest cancer may be present, without requiring a CT scan or invasive procedure.

Trial Status

SimpleScreen Lung was launched commercially on October 20, 2026 as a laboratory-developed test (LDT) through Freenome's CLIA-certified lab. Clinical validation data was presented at the 2026 AACR Annual Meeting, showing 85% sensitivity and 99.8% negative predictive value in an independent cohort. The FDA granted Breakthrough Device Designation on August 12, 2026, which supports an eventual premarket approval submission, though no submission date has been announced.

The Two-Sided Case

▲ Bull Case5
SimpleScreen Lung showed 85% sensitivity and 99.8% negative predictive value in an independent cohort, a strong performance for a blood-based lung cancer screening test in a high-risk population (ages 50-80, >=20 pack-year smoking history).
The test is commercially launched and can be ordered alongside the FDA-approved SimpleScreen CRC test from a single blood draw, offering a differentiated 'personalized cancer detection' bundle.
Freenome has FDA Breakthrough Device Designation for SimpleScreen Lung, which provides prioritized review and enhanced FDA interaction for a future premarket approval submission.
Revenue momentum: Q3 2026 revenue was $183.5M, driven by the SimpleScreen CRC approval, and the company has ~$410M cash. Major institutional investors (ARK, UBS, Alphabet, FMR, BlackRock) took new positions in Q3 2026.
Analyst consensus is Strong Buy (10 Buy/Strong Buy, 1 Hold) with a mean price target of $18, representing ~73% upside from the current $10.41 close.
▼ Bear Case5
SimpleScreen Lung is launched as an LDT, not a fully FDA-approved test, which could limit physician adoption and payer reimbursement compared to FDA-authorized alternatives.
Lung cancer screening competition is intense: GRAIL's multi-cancer Galleri test received an FDA advisory panel endorsement in September 2026, while Guardant Health and Exact Sciences are expanding into multi-cancer blood testing.
At 50% specificity, SimpleScreen Lung may produce false positives in half of screened patients, potentially limiting clinical adoption versus tests with higher specificity.
The company is newly public via SPAC (July 2026) and unprofitable; the stock has declined from highs near $17.50 to $10.41, suggesting post-SPAC de-risking pressure.
The CEO sold shares via tax-withholding (72K shares at $15.25 in September 2026), the only insider trade in the last 90 days.

Upcoming Catalysts

  • Potential FDA premarket approval (PMA) submission for SimpleScreen Lung (no date announced)
  • Commercial adoption metrics and physician uptake of the LDT
  • Payer coverage and reimbursement decisions for the lung cancer screening test
  • Data updates at medical conferences (e.g., future AACR, ASCO presentations)

Source Filing

The SEC filing that triggered this drug report:

Freenome, Inc. SEC filing FRNM ·Accession 0002017526-26-000019

Sources · 7

Hover a chip for the title
1 morningstar.com2 morningstar.com3 newspressnow.com4 cancernetwork.com5 seekingalpha.com6 msn.com7 streetinsider.com